John Rutkowski, MD
Urology · Sanborn, NYNPI 1902061914
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Intuitive Surgical at 35.5% of the total.
Across 157 payments — averaging $40.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Janssen Scientific Affairs, LLC$818
- Astellas Pharma US Inc$815
- Johnson & Johnson$368
- Sumitomo Pharma America, Inc.$329
- AbbVie$238
- plus $1K from 20 others
Across 73 payments — averaging $4359.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$261K
- Ferring Pharmaceuticals AS$58K
What the payments were for
- Consulting fees$81813%
- Travel & lodging$2,01132%
- Food & beverage$3,26652%
- Education$2003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $2,237 |
| Janssen Scientific Affairs, LLC | 1 | $818 |
| Astellas Pharma US Inc | 41 | $815 |
| Johnson & Johnson(2 entities) | 14 | $368 |
| Sumitomo Pharma America, Inc. | 13 | $329 |
| AbbVie(2 entities) | 13 | $238 |
| Medtronic | 4 | $233 |
| Bayer | 7 | $163 |
| Boston Scientific | 2 | $149 |
| Pfizer | 8 | $139 |
| Merck | 5 | $122 |
| Endogastric Solutions, Inc | 1 | $120 |
| Ferring Pharmaceuticals Inc. | 6 | $108 |
| Myriad Genetic Laboratories, Inc. | 5 | $83 |
| Olympus America Inc. | 2 | $58 |
| Tolmar Pharmaceuticals, Inc. | 3 | $53 |
| Urogen Pharma, Inc. | 2 | $51 |
| Urovant Sciences Inc | 3 | $38 |
| Novartis | 2 | $38 |
| Acera Surgical, Inc. | 1 | $30 |
| Calyxo, Inc. | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
| Axonics, Inc. | 1 | $19 |
| 180 Medical, Inc. | 1 | $18 |
| Covidien LP | 1 | $12 |
| Ambu Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,034
- Erleada$818
- ORGOVYX$133
- LigaSure$121
- ESOPHYX$120
- RYBREVANT$118
- CARVYKTI$118
- GENERAL ERECTILE DYSFUNCTION$112
How this compares
$6,294 in reported general payments places this provider in the 70th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 633 | $7,967,847 |
| NubeqaDarolutamide | 244 | $3,198,846 |
| Abiraterone Acetate | 400 | $1,247,913 |
| ErleadaApalutamide | 29 | $431,813 |
| MyrbetriqMirabegron | 268 | $198,864 |
| OrgovyxRelugolix | 47 | $122,169 |
| GemtesaVibegron | 32 | $31,832 |
| Mirabegron ErMirabegron | 26 | $15,182 |
| Tamsulosin Hcl | 599 | $11,211 |
| Finasteride | 355 | $5,719 |
| Estradiol | 46 | $3,448 |
| Potassium Citrate ErPotassium Citrate | 52 | $3,288 |
| Silodosin | 39 | $3,095 |
| Prednisone | 417 | $2,608 |
| Trospium Chloride ErTrospium Chloride | 11 | $2,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $815 | $8,166,712901 claims |
| BayerNubeqa | $163 | $3,198,846244 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $818 | $1,247,913400 claims |
| Johnson & JohnsonErleada | $368 | $431,81329 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $329 | $154,00179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 urology providers in New York.
Other urology in Sanborn
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.